Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $189.00 at TD Cowen

Becton, Dickinson and Company (NYSE:BDX) had its target price raised by TD Cowen from $183.00 to $189.00 in a research note issued to investors on Wednesday morning,MarketScreener reports. They currently have a hold rating on the medical instruments supplier’s stock.

A number of other brokerages also recently weighed in on BDX. JPMorgan Chase & Co. lowered their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday. Wells Fargo & Company dropped their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Jefferies Financial Group lowered their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Trading Down 0.4%

Shares of BDX traded down $0.72 during mid-day trading on Wednesday, reaching $179.90. 489,114 shares of the company were exchanged, compared to its average volume of 2,197,937. The business has a 50 day simple moving average of $199.49 and a two-hundred day simple moving average of $192.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. The stock has a market capitalization of $51.22 billion, a PE ratio of 29.35, a PEG ratio of 1.90 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the prior year, the business posted $3.43 earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 2,463 shares of company stock valued at $501,530 in the last 90 days. 0.40% of the stock is owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

Several institutional investors have recently made changes to their positions in BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC lifted its holdings in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the period. Callan Family Office LLC purchased a new position in Becton, Dickinson and Company in the second quarter worth $324,000. CWM LLC grew its stake in Becton, Dickinson and Company by 87.7% in the 2nd quarter. CWM LLC now owns 22,596 shares of the medical instruments supplier’s stock valued at $3,892,000 after purchasing an additional 10,560 shares during the period. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 43.6% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,441 shares of the medical instruments supplier’s stock worth $1,454,000 after purchasing an additional 2,562 shares during the period. Institutional investors own 86.97% of the company’s stock.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD completed the Biosciences & Diagnostics spin‑off and merged that business with Waters, unlocking roughly $4.0B in proceeds as BD pivots to a pure‑play medtech profile. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Recent quarter showed a sales/earnings beat and management set FY2026 EPS guidance — the company says portfolio reshaping and product investments are helping offset tariff headwinds. These operational positives support longer‑term margins and the medtech pivot. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Positive Sentiment: BD launched cash tender offers to repurchase up to $1.6B of outstanding debt — a credit‑friendly move that can lower interest expense and improve leverage metrics if executed. Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
• Neutral Sentiment: Citigroup trimmed its price target modestly (to $232) but kept a buy rating — a small revision that signals confidence in the longer‑term thesis despite near‑term pressure. Citigroup Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $232.00
• Neutral Sentiment: Some brokers (Jefferies, RBC) have lowered targets but maintained positive ratings on structural improvements — signaling divergence among analysts on near‑term vs. strategic outlooks. What’s Going On With Becton Dickinson Stock Tuesday?
• Negative Sentiment: JPMorgan issued a more pessimistic forecast and trimmed its price target, weighing on sentiment and contributing to intraday selling pressure. JPMorgan Chase & Co. Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Wells Fargo lowered its target substantially and moved to an in‑line/equal‑weight view, another downshift that adds selling pressure given wide circulation of the note. Wells Fargo & Company Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Multiple analyst downgrades/target cuts triggered a gap down in the stock and are the primary cause of the share‑price weakness despite the company’s strategic and operational positives. Becton, Dickinson and Company (NYSE:BDX) Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.